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March 29, 2011:1496–500elegantly showed an association between a variant (SNP
rs1333049) on chromosome 9p21 and coronary artery disease
(CAD) severity represented by the number of coronary arteries
with 50% stenosis in 2 cohorts of CAD patients who did not
have diabetes mellitus (1). This provides novel evidence for an
influence on the extent of coronary arterial lesions by the 9p21
variant, which was identified recently by genome-wide association
studies to be a major genetic determinant that increases the risk of
CAD.
Interestingly, several previous studies did not find the association
between 9p21 and CAD severity defined by the number of coronary
arteries with significant stenosis (3–5). In their report, Dandona et al.
(1) speculated on several possible explanations, 1 of which is the
nclusion of CAD patients with diabetes mellitus in the previously
tudies, which might confound and obscure the effect of 9p21 on
AD.
To investigate this possibility, we undertook analyses in a cohort of
AD patients (mean age 63 years, n 1,094) recruited previously in
he SAS (Southampton Atherosclerosis Study) (6). The subjects had
50% stenosis in at least 1 major epicardial coronary artery and were
ll of European ancestry. When CAD patients with diabetes mellitus
n 146) were excluded, we observed an association between the risk
llele (C allele) of the 9p21 SNP rs1333049 and increased risk of
-vessel disease (3VD) defined by 50% stenosis in the 3 major
oronary arteries (p  0.022) (Fig. 1). Logistic regression analysis
howed that each copy of the risk allele was associated with a 30%
ncreased risk of 3VD (odds ratio: 1.30 [95% confidence interval: 1.04
o 1.63]) after adjusting for age, sex, smoking, hypertension, hyper-
holesterolemia, lipid-lowering treatment, and body mass index.
owever, when the CAD patients with diabetes mellitus were
ncluded in the analysis, the relationship between SNP rs1333049 and
AD severity became nonsignificant statistically (p  0.077). This
nding is in line with the possibility of an obscuring effect of diabetes
ellitus, suggested by Dandona et al. (1).
Thus, the results of our study support that there is an association
Figure 1 Association of 9p21 Genotype With Severity of CAD
Presented in the column chart are percentages of patients with 3-vessel dis-
ease (3VD) (n  223) as a function of genotype. The p value was derived from
logistic regression analysis with adjustment for age, sex, smoking, hyperten-
sion, hypercholesterolemia, lipid-lowering treatment, and body mass index.
Patients with diabetes mellitus were excluded. CAD  coronary artery disease.etween 9p21 and CAD severity, arguing for the notion that thep21 variant predisposes to initiation as well as progression of
AD (2). In addition, our data highlight the need for further
etailed studies to assess the effects of 9p21 on CAD phenotypes
nd its potential interactions with other cardiovascular risk factors
uch as diabetes mellitus.
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We thank Mr. Chan and colleagues for the interest in our paper
(1). They are able to replicate the association of gene dosage of the
risk variant located at 9p21 and severity of coronary artery disease
(CAD) in the SAS (Southampton Atherosclerosis Study) when
diabetic patients are excluded from their analysis. However, when
diabetic patients are included, this association no longer achieves
statistical significance. Given the findings of Doria et al. (2) that
poor glycemic control tended to amplify the risk association of
CAD with 9p21, we had postulated in our original paper that the
inability to demonstrate such an association in other cohorts might
potentially have been secondary to a confounding effect of diabetes
(1). The finding of Mr. Chan and colleagues would lend credence
to this hypothesis. We do recognize that further similar confirma-
tory studies are required. However, these findings do underscore
the need for meticulous phenotyping in genetic association studies.
Furthermore, it demonstrates the potential complex interplay
RR
m
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March 29, 2011:1496–500between genotype, the phenotype of interest, and other associated
disease processes that may obscure the finding of such associations.
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Heart Failure With
Normal Ejection Fraction
The Diagnostic Importance
of Left Atrial Volume
Heart failure with normal ejection fraction (HFNEF) is common
and causes considerable morbidity, but treatment options are
limited, and the pathophysiology of HFNEF remains incompletely
understood (1). A factor that has hampered research into HFNEF
has been the lack of a gold standard for noninvasive diagnosis.
Although echocardiography is very good at demonstrating normal
left ventricular ejection fraction, Doppler techniques for estimation
of diastolic function and left atrial (LA) pressure are less reliable
(2) and are complex (3). In contrast, calculation of LA volume is
a simple technique, and although not the gold standard for
HFNEF diagnosis, increased LA volume index is associated with
more severe abnormalities of diastolic function and is an indepen-
dent predictor for the development of congestive heart failure (4).
Furthermore, there is a biologically plausible explanation for the
diagnostic and prognostic significance of increased LA volume,
which is that LA remodeling occurs as a result of chronic elevation
of LA pressure. In dyspneic subjects with normal left ventricular
ejection fraction, the finding of LA dilation provides support that
the dyspnea is due to HFNEF. Conversely, the absence of LA
dilation in such individuals argues against a cardiac cause of
dyspnea even in the presence of Doppler abnormalities of diastolic
function (4). Such findings have resulted in increased recognition
of the importance of LA volume assessment in recent diastolic
function guidelines (3,5).
Given the importance of LA size and the ease of its assessment,
we believe it is vital for the interpretation of HFNEF that LA
volume is always reported. There is even a strong rationale why LA
dilation might be considered an eligibility criterion for studies ofHFNEF. However, that such an approach is not current practice
is evident in 2 recent studies with potential to provide valuable
insights into the factors that may predispose to exercise intolerance
in HFNEF (6,7). In a study from Borlaug et al. (6) of HFNEF
subjects selected based on Framingham criteria, LA size was not
reported at all. In a study from Maeder et al. (7) of subjects with
suspected HFNEF, LA volume index was in the normal range and
not significantly higher than controls. Although this finding was
not discussed by the authors, it raised 2 important possibilities for
the interpretation of the study: either the study group may have
included subjects who did not have HFNEF, or alternatively, there
is a subgroup of subjects with HFNEF who do not develop LA
dilation.
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We thank Dr. Mottram and colleagues for their interest in our
paper (1). We agree that left atrial volume is a useful diagnostic
marker of chronic heart failure with preserved ejection fraction
(HFpEF). In our study (1), mean left atrial volume was 45  13
l/m2 in HFpEF patients, 31  8 ml/m2 in hypertensive patients
p  0.001 vs. HFpEF), and 29  5 ml/m2 in controls (p  0.005
vs. HFpEF, p  0.5 vs. hypertensive patients). These values are
similar to or in excess of those reported in HFpEF patients in
previous studies (2,3), and are certainly consistent with the
diagnosis of chronic HFpEF in our cohort.
